Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel.
Beshore
Douglas C
DC
Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., Inc., West Point, PA 19486, USA. douglas_beshore@merck.com
Liverton
Nigel J
NJ
McIntyre
Charles J
CJ
Claiborne
Christopher F
CF
Libby
Brian
B
Culberson
J Christopher
JC
Salata
Joseph J
JJ
Regan
Christopher P
CP
Lynch
Joseph J
JJ
Kiss
Laszlo
L
Spencer
Robert H
RH
Kane
Stephanie A
SA
White
Rebecca B
RB
Yeh
Suzie
S
Hartman
George D
GD
Dinsmore
Christopher J
CJ
D000818:Animals; D004305:Dose-Response Relationship, Drug; D055808:Drug Discovery; D004353:Drug Evaluation, Preclinical; D004983:Ethanolamines / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D026902:Potassium Channel Blockers / Q000737:chemistry / Q000494:pharmacology*; D024642:Potassium Channels, Voltage-Gated / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
D004983:Ethanolamines; C109966:KCNF1 protein, human; D026902:Potassium Channel Blockers; D024642:Potassium Channels, Voltage-Gated